CATUVAB®
Intraoperative blood salvage during cancer surgery (tumor cell removal)
Key Facts
About Lindis Blood Care
Lindis Blood Care is a private, clinical-stage MedTech company pioneering the Antibody-Based Cell Removal Technology (ABCR-T) platform. Its lead product, CATUVAB®, is a medical device designed to enable safe autologous blood transfusion in oncological surgeries by removing tumor cells from salvaged blood, thereby reducing reliance on donor blood. The company has completed a pivotal multicenter study (REMOVE) with 136 patients, is preparing for an EU launch in Q4 2025, and is actively seeking distribution and licensing partners globally. Lindis Blood Care operates in the hematology and medical device sectors, addressing a critical need in surgical oncology and transfusion medicine.
View full company profile